Ritter Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13
2018年3月5日 - 8:00PM
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of novel
therapeutics that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on establishing the
first FDA-approved treatment for lactose intolerance, today
announced that the Company will present at the 30th Annual ROTH
Conference on March 13, 2018, at 8:00 a.m. PT in Dana Point,
California.
Ritter Pharmaceuticals’ management team will
also be available to participate in one-on-one meetings with
investors on March 12-13. Conference participants who are
interested in scheduling a meeting should Email
oneononerequests@roth.com.
The conference will be held March 11-14, 2018,
at the Ritz Carlton in Dana Point, California.
The Company’s presentation will be available for
the public to access at www.ritterpharma.com.
About Ritter
Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. The Company’s lead product, RP‐G28, has the potential to
become the first FDA‐approved treatment for lactose intolerance, a
condition that affects millions worldwide. RP-G28 has been studied
in Phase 2 trials and is now in Phase 3 clinical development. The
Company is further exploring the functionality and discovering the
therapeutic potential gut microbiome changes may have on
treating/preventing a variety of conditions including:
gastrointestinal diseases, immuno‐oncology, metabolic, and liver
disease.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements refer to
future plans and expectations, including statements regarding the
timing of our first Phase 3 pivotal clinical trial. Management
believes that these forward-looking statements are reasonable as
and when made. However, such statements involve a number of
known and unknown risks and uncertainties that could cause the
Company’s future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Factors
that could affect the Company’s actual results are included in the
Company’s SEC filings, including the Company’s most recent reports
on Form 10-K and 10-Q filed with the SEC. These forward-looking
statements are made only as of the date hereof, and, except as
required by law, the Company undertakes no obligation to update or
revise its forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts Investor Contact:Jeffrey Benjamin
310-203-1000 jeffrey@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024